Forbion Co-leads $100 Million Series A Funding in Navigator Medicines to Advance Development of Best-in-class antibody therapeutics for autoimmune diseases.

• Financing co-led by Forbion Growth Opportunities Fund II and RA Capital
• Round will support the development of lead asset NAV-240, a potential best-in-class bispecific antibody targeting OX40L and TNFα, currently in Phase 1 development for complex autoimmune diseases and as well as a broader pipeline of OX40L-targeted mono- and bispecific antibodies
• Wouter Joustra, General Partner at Forbion to join the Board of Directors

Naarden, August 27, 2024 – Forbion, a leading global life sciences venture capital firm with deep expertise in Europe , today announces its participation as lead investor in the closing of a $100M Series A financing in Navigator Medicines, Inc. (“Navigator”). Navigator is leading the advancement of biologics for targeted immune regulation & restoration, specializing in bispecific antibodies for autoimmune diseases. Forbion co-led the Series A financing together with RA Capital. The funds will support the further development of Navigator’s lead program NAV-240, a clinical-stage bispecific antibody against OX40L and TNFα, as well as a pipeline of OX40L-targeted mono- and bispecific antibodies. Wouter Joustra, General Partner at Forbion, will join Navigator’s Board of Directors. Mathias Vinther, Principal, will join as Board Observer.

Navigator is a biotechnology company advancing a pipeline of OX40L-targeted mono- and bispecific antibodies with lead program NAV-240 currently in Phase 1 development. NAV-240 targets two clinically-validated pathways, OX40L and TNFα, that are critical in the pathogenesis of several inflammatory diseases. Dual targeting of both pathways may improve upon the efficacy of either monotherapy alone as a potential treatment option for complex, heterogenous diseases with unmet medical needs, such as hidradenitis suppurativa (HS) and rheumatoid arthritis (RA).